This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vermersch, P Articles by Stojkovic, T Search for Related Content PubMed PubMed Citation Articles by Vermersch, P Articles by Stojkovic, T Social Bookmarking                         What's this?

Quality of life in multiple sclerosis: influence of interferon-ß1a (Avonex®) treatment

Department of Neurology, Hôpital R. Salengro, Lille 59037, France, pvermersch{at}chru-lille.fr

J de Seze

Department of Neurology, Hôpital R. Salengro, Lille 59037, France

B Delisse

Department of Neurology, Centre Hospitalier Schaeffner, Lens 62300, France

S Lemaire

Department of Neurology, Hôpital R. Salengro, Lille 59037, France

T Stojkovic

Department of Neurology, Hôpital R. Salengro, Lille 59037, France

Background: Numerous data argue for initiating treatment with interferon-ß(IFN-ß) at an early stage in multiple sclerosis (MS). The consequences of its use may negatively influence the MS patient’s quality of life (QoL). Objective: To evaluate the QoL of MS patients before and after a one-year period of treatment with IFN-ß1a (Avonex®). Patients and Methods: QoL was assessed using the SF-36 in 121 relapsing-remitting MS patients. We compared QoL before and after treatment and with data from a normal population. We also studied the possible influence of disease progression on the SF-36 scores. Results: One hundred six patients completed the study (87%). Compared to a normal population, patients were, at baseline, worse off for all QoL scales, varying from a minimum decrease of 0.73 SD in mental health, to a maximum decrease of 1.55 SD in general health. After treatment, we found no significant changes in any of the QoL scores, except for physical function, where we noted a slight but significant decrease (p=0.03). Furthermore, there was no significant change either in the physical component summary (PCS) or mental component summary (MCS). The ‘reported health transition’ item was significantly improved compared to baseline (p=0.001). At inclusion, significant correlations were found between EDSS scores and scores of physical function (p<0.001), role - physical (p<0.01), general health and social function (both p<0.01), and with the PCS (p<0.01). Patients with clinical relapses and/or disability progression had a more significant decrease in physical function (p<0.05) and also in social function (p<0.05). Conclusion: The QoL, assessed by the SF-36 scale, is correlated with disability in MS. IFN-ß1a treatment (Avonex®) has no negative effect on MS patient’s QoL.

Key Words: interferon-ß1a • multiple sclerosis • quality of life

Multiple Sclerosis, Vol. 8, No. 5, 377-381 (2002)
DOI: 10.1191/1352458502ms826oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E M Mowry, M J Loguidice, A B Daniels, D A Jacobs, C E Markowitz, S L Galetta, M L Nano-Schiavi, G R Cutter, M G Maguire, and L J Balcer Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity J. Neurol. Neurosurg. Psychiatry, July 1, 2009; 80(7): 767 - 772. [Abstract] [Full Text] [PDF]

				K.V.L. Turpin, L.J. Carroll, J.D. Cassidy, and W.J. Hader Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs Multiple Sclerosis, September 1, 2007; 13(8): 1038 - 1045. [Abstract] [PDF]

				A.G. Beiske, H. Naess, J.H. Aarseth, O. Andersen, I. Elovaara, M. Farkkila, H.J. Hansen, S.I. Mellgren, M. Sandberg-Wollheim, P.S. Sorensen, et al. Health-related quality of life in secondary progressive multiple sclerosis Multiple Sclerosis, April 1, 2007; 13(3): 386 - 392. [Abstract] [PDF]

				O Lily, E McFadden, E Hensor, M Johnson, and H Ford Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment Multiple Sclerosis, November 1, 2006; 12(6): 808 - 813. [Abstract] [PDF]

				L. Hemmett, J. Holmes, M. Barnes, and N. Russell What drives quality of life in multiple sclerosis? QJM, October 1, 2004; 97(10): 671 - 676. [Abstract] [Full Text] [PDF]